سعر جاستروفيت 500 مجم 20 اقراص 2026

Sucralfate 500 mg tablets, 20 per pack, by EIPICO.

• Adverse reactions in clinical trials were minor (4.7% of patients); constipation was most frequent (2%). Postmarketing: hypersensitivity reactions (urticaria, angioedema, respiratory difficulty, rhinitis, laryngospasm, facial swelling), bezoars.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to sucralfate or any component of the tablet.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Aluminium can accumulate in chronic renal failure and dialysis (aluminium osteodystrophy, osteomalacia, encephalopathy). Tablet aspiration has occurred in patients with impaired swallowing or altered gag reflex.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Cimetidine, digoxin, fluoroquinolones, ketoconazole, levothyroxine, phenytoin, quinidine, ranitidine, tetracycline, theophyllineSucralfate may reduce the bioavailability of these drugs; administer separately when altered absorption could be critical (in studies, giving the other drug 2 hours before sucralfate eliminated the interaction). Subtherapeutic prothrombin times with warfarin have been reported.DailyMed (U.S. National Library of Medicine)
• AntacidsAntacids may be used as needed for pain relief but should not be taken within one-half hour before or after sucralfate.DailyMed (U.S. National Library of Medicine)

• Animal reproduction studies at doses up to 50 times the human dose showed no evidence of fetal harm; there are no adequate and well-controlled studies in pregnant women, so use only if clearly needed.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• It is not known whether sucralfate is excreted in human milk; exercise caution when given to a nursing woman.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Sucralfate: Acts locally: forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site, a barrier to hydrogen-ion diffusion; inhibits pepsin activity and adsorbs bile salts; minimally absorbed (US label).